Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin N Rome
Aaron S Kesselheim

Showing results (1-10 of 477) with videos related to

Pageof 48
Sort By:
Health Affairs (Project Hope)|December 6, 2021
Raising Medicaid Rebates For Drugs With Accelerated ApprovalBenjamin N Rome, Aaron S Kesselheim
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 21, 2019
Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic AnalysisBenjamin N Rome, Aaron S Kesselheim
BMJ (Clinical Research Ed.)|September 9, 2021
Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational studyBishal Gyawali, Benjamin N Rome, Aaron S Kesselheim
Journal of Managed Care & Specialty Pharmacy|October 31, 2025
Halting hyaluronidase hopping to maintain the integrity of Medicare drug price negotiationJohn Kim, Aaron S Kesselheim, Benjamin N Rome
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 29, 2022
State Laws and Generic Substitution in the Year After New Generic CompetitionBenjamin N Rome, Ameet Sarpatwari, Aaron S Kesselheim
The American Journal of Managed Care|November 25, 2025
US spending on high-revenue rare disease drugs in 2022Helen Mooney, Aaron S Kesselheim, Benjamin N Rome
The American Journal of Managed Care|March 16, 2026
Biosimilar interchangeability and substitution in the US: what comes next?Benjamin N Rome, Anushka Bhaskar, Aaron S Kesselheim
Health Affairs (Project Hope)|May 3, 2021
Frequency Of Generic Drug Price Spikes And Impact On Medicaid SpendingAayan N Patel, Aaron S Kesselheim, Benjamin N Rome
JAMA|April 18, 2023
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in MedicareAlexander C Egilman, Benjamin N Rome, Aaron S Kesselheim
Clinical Pharmacology and Therapeutics|July 13, 2020
Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018Benjamin N Rome, ChangWon C Lee, Aaron S Kesselheim
Pageof 48

Showing results (1-10 of 477) with videos related to

Sort By:
Pageof 48
Health Affairs (Project Hope)|December 6, 2021
Raising Medicaid Rebates For Drugs With Accelerated ApprovalBenjamin N Rome, Aaron S Kesselheim
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 21, 2019
Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic AnalysisBenjamin N Rome, Aaron S Kesselheim
BMJ (Clinical Research Ed.)|September 9, 2021
Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational studyBishal Gyawali, Benjamin N Rome, Aaron S Kesselheim
Journal of Managed Care & Specialty Pharmacy|October 31, 2025
Halting hyaluronidase hopping to maintain the integrity of Medicare drug price negotiationJohn Kim, Aaron S Kesselheim, Benjamin N Rome
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 29, 2022
State Laws and Generic Substitution in the Year After New Generic CompetitionBenjamin N Rome, Ameet Sarpatwari, Aaron S Kesselheim
The American Journal of Managed Care|November 25, 2025
US spending on high-revenue rare disease drugs in 2022Helen Mooney, Aaron S Kesselheim, Benjamin N Rome
The American Journal of Managed Care|March 16, 2026
Biosimilar interchangeability and substitution in the US: what comes next?Benjamin N Rome, Anushka Bhaskar, Aaron S Kesselheim
Health Affairs (Project Hope)|May 3, 2021
Frequency Of Generic Drug Price Spikes And Impact On Medicaid SpendingAayan N Patel, Aaron S Kesselheim, Benjamin N Rome
JAMA|April 18, 2023
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in MedicareAlexander C Egilman, Benjamin N Rome, Aaron S Kesselheim
Clinical Pharmacology and Therapeutics|July 13, 2020
Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018Benjamin N Rome, ChangWon C Lee, Aaron S Kesselheim
Pageof 48